---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-125866"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2025-05-23T23:59:59+00:00"
generated_at: "2026-05-20T14:49:58.999103+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# COO Brett Kaplan departs Climb Bio; CEO Aoife Brennan named interim PFO

## Summary
- Brett Kaplan, COO and principal financial officer, separated mutually on May 23, 2025.
- Kaplan receives severance: 3 months base salary ($128,749.99) plus COBRA for 3 months.
- CEO Aoife Brennan appointed interim principal financial officer, effective May 24, 2025, retaining CEO role.
- No changes to Brennan's compensation or arrangements in connection with this appointment.
- Kaplan reaffirms confidentiality, non-compete (amended to exclude CD19/APRIL drugs), and non-solicitation obligations.

## SEC filing metadata
- accession: 0001193125-25-125866
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2025-05-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312525125866/0001193125-25-125866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312525125866/d854335d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-125866
- JSON: https://secwatch.observer/filing/0001193125-25-125866.json
- Plain text: https://secwatch.observer/filing/0001193125-25-125866.txt

## Key facts
- Executive change
  Brett Kaplan departed as Chief Operating Officer and principal financial officer at Climb Bio, Inc..
  - Action: separated
  - Role: Chief Operating Officer and principal financial officer
  source text: On May 23, 2025, Climb Bio, Inc. (the “Company”) and Brett Kaplan, M.D., its Chief Operating Officer and principal financial officer, mutually agreed that Dr. Kaplan would separate from the Company, effective May 23, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768446/000119312525125866/0001193125-25-125866-index.htm
- Executive change
  Aoife Brennan was appointed as interim principal financial officer at Climb Bio, Inc..
  - Action: appointed
  - Role: interim principal financial officer
  source text: On the Separation Date, the Board of Directors of the Company appointed Aoife Brennan as the Company’s interim principal financial officer, effective as of May 24, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768446/000119312525125866/0001193125-25-125866-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.